Scynexis Q2 swings to profit on warrant adjustment; advances drug studies

Scynexis

10/08/2026 21:41

Overview
US biotech firm's Q2 license agreement revenue fell sharply yr/yr
Company posted net income in Q2, driven by warrant liability fair value adjustment
R&D expenses dropped 46% yr/yr, while cash runway extends into 2029

Outlook
Company expects topline data from Phase 1 SCY-770 study in Q3 2026
Scynexis plans to initiate Phase 2 SCY-770 study in ADPKD in Q4 2026
Company expects current cash position to fund operations into 2029

Result Drivers
R&D EXPENSES - Co said Q2 R&D expenses fell 46% yr/yr, mainly due to lower chemistry, manufacturing, controls, preclinical, and clinical costs
WARRANT LIABILITY ADJUSTMENT - Net income was mainly driven by a fair value adjustment related to warrant liabilities due to a decrease in stock price
CLINICAL PROGRESS - Co initiated Phase 1 study for SCY-770 and completed dosing in Phase 1 study for SCY-247

Company press release: ID:nGNX7TK4nS

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 License Agreement Revenue
 
$235,000
 
Q2 Net Income
 
$7.40 mln
 
Q2 Basic EPS
 
$0.63
 
Q2 Operating Expenses
 
$8.01 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for SCYNEXIS Inc is $32.00, about 510.7% above its August 7 closing price of $5.24

Reuters Recommended Reads
Aug 10 - Biohaven Q2 net loss narrows on lower R&D spend
Aug 10 - Metagenomi Q2 net loss widens cash runway seen through 2027
Aug 10 - Sionna scraps genetic disorder drug program after trial setback; shares tank

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)